Bio-immunotherapy of cancer provides compelling proof of clinical success in the comprehensive treatment of human malignancies. The Italian Network for Cancer Biotherapy (NIBIT), a non-profit association established in 2004, gathers national groups focused on clinical and pre-clinical research in cancer immunotherapy and biotherapy each year to discuss the latest advances in the field. The NIBIT has convened the international meeting "Cancer Bio-Immunotherapy in Siena" together with its XVth annual Congress.
Aiman Shalabi, Pharm.D., MBA, BCOP, chief medical officer of the Cancer Research Institute, presents on Saturday, October 7, 2017 in the "Prospective NIBIT and NIBIT Foundation collaborations" session.
“A Vision of I-O: The Siena Consensus," a think tank meeting convened by the NIBIT Foundation, will immediately follow the meeting on October 7, 2017 (3:00pm-6:00pm) in Siena, Italy. Aiman Shalabi in attendance. Topics for discussion include:
- Agonistic antibodies in the era of antagonistic antibodies: monotherapy, combination and/or sequence
Introduced by: Bernie Fox (WIC/KOL) and Axel Hoos (GSK)
- A common denominator among I-O "Omics (mutatome, transcriptome, epigenome, metabolome, proteome, microbiome, etc) to drive the future of immunotherapy: a reachable goal or simply an utopia?
Introduced by: George Coukos (KOL) and Dominik Ruettinger (Roche)
- Pharmacodynamic biomarkers in the peripheral blood: a worth exploring field
Introduced by: Jedd Wolchok (KOL) and Jean Viallet (BMS)
- Bringing to reality novel ideas from young scientists: can "The Siena I-O Consensus Panel" help?
Introduced by: Ramy Ibrahim (Parker) and Wolf Fridman (KOL)